Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.04.14	Press Release: New data at AAN to confirm -2- (Dow Jones)
23.04.14	Press Release: New data at AAN to confirm efficacy of Novartis' Gilenya(R) across four key measures of MS disease activity, including brain volume loss (Dow Jones)
22.04.14	Press Release: Novartis announces portfolio -2- (Dow Jones)
22.04.14	Press Release: Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, E... (Dow Jones)
09.04.14	Press Release: Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz (Dow Jones)
07.04.14	Press Release: Novartis meningitis B vaccine -2- (Dow Jones)
03.04.14	Press Release: Novartis data on 19 compounds at -2- (Dow Jones)
03.04.14	Press Release: Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways (Dow Jones)
31.03.14	Press Release: PARADIGM-HF trial of Novartis' -2- (Dow Jones)
31.03.14	Press Release: PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results (Dow Jones)
27.03.14	Press Release: Novartis to work with FDA on path -2- (Dow Jones)
27.03.14	Press Release: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome (Dow Jones)
27.03.14	Press Release: Novartis study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC (Dow Jones)
26.03.14	Press Release: Novartis study published in NEJM -2- (Dow Jones)
26.03.14	Press Release: Novartis study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC (Dow Jones)
22.03.14	Press Release: New phase III psoriasis data show -3- (Dow Jones)
22.03.14	Press Release: New phase III psoriasis data show -2- (Dow Jones)
22.03.14	Press Release: New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis' secukinumab (AIN457) (Dow Jones)
21.03.14	Press Release: Novartis announces US FDA approval -2- (Dow Jones)
21.03.14	Press Release: Novartis announces US FDA approval of Xolair(R) for chronic idiopathic urticaria (CIU) (Dow Jones)
21.03.14	Press Release: UK recommends Novartis Bexsero(R) -2- (Dow Jones)
21.03.14	Press Release: UK recommends Novartis Bexsero(R) vaccine for inclusion in National Immunisation Programme to help protect against devastating meningitis B (Dow Jones)
21.03.14	Press Release: Novartis announces start of new -2- (Dow Jones)
21.03.14	Press Release: Novartis announces start of new secukinumab (AIN457) versus Stelara(R) (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014 (Dow Jones)
20.03.14	Press Release: Novartis introduces Lucentis(R) in state of the art pre-filled syringe (Dow Jones)
19.03.14	Press Release: Novartis reports data at EBCC-9 -2- (Dow Jones)
19.03.14	Press Release: Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer (Dow Jones)
13.03.14	Press Release: Novartis Bexsero(R) meningitis B -2- (Dow Jones)
13.03.14	Press Release: Novartis Bexsero(R) meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia (Dow Jones)
07.03.14	Press Release: Novartis announces positive Phase -2- (Dow Jones)
07.03.14	Press Release: Novartis announces positive Phase III study for Jakavi(R) in patients with rare blood cancer polycythemia vera (Dow Jones)
06.03.14	Press Release: Novartis announces Xolair(R) -2- (Dow Jones)
06.03.14	Press Release: Novartis announces Xolair(R) approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive t... (Dow Jones)
28.02.14	Thomson Reuters ONE/Novartis ruft im Rahmen des -2- (Dow Jones)
28.02.14	Thomson Reuters ONE/Novartis ruft im Rahmen des "Rare Disease Day" dazu auf, mehr in die Forschung von seltenen Krankheiten zu investieren - für ein besse... (Dow Jones)
28.02.14	Thomson Reuters ONE/Novartis marque la Journée -2- (Dow Jones)
28.02.14	Thomson Reuters ONE/Novartis marque la Journée internationale des maladies rares par un appel à intensifier la recherche pour comprendre les maladies rare... (Dow Jones)
28.02.14	Press Release: Novartis marks Rare Disease Day -2- (Dow Jones)
26.02.14	Press Release: Novartis extends leadership in clinical trial data transparency, reinforcing its support of clinical research and innovation (Dow Jones)
25.02.14	Thomson Reuters ONE/Les actionnaires de Novartis -2- (Dow Jones)
25.02.14	Press Release: Novartis shareholders approve all -2- (Dow Jones)
25.02.14	Thomson Reuters ONE/Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration (Dow Jones)
25.02.14	Press Release: Novartis shareholders approve all resolutions proposed by Novartis Board of Directors (Dow Jones)
24.02.14	Press Release: Novartis provides second US -2- (Dow Jones)
24.02.14	Press Release: Novartis provides second US university with Bexsero(R) to help protect students and staff against potentially deadly meningitis B disease (Dow Jones)
21.02.14	Press Release: Novartis shows continued -2- (Dow Jones)
21.02.14	Press Release: Novartis shows continued commitment in Japan with Lucentis(R) approval in fourth Japanese indication, diabetic macular edema (Dow Jones)
19.02.14	Press Release: Novartis investigational compound -2- (Dow Jones)
19.02.14	Press Release: Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma (Dow Jones)
17.02.14	Press Release: Novartis expands cancer immunotherapy research program with acquisition of CoStim (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert